Table 2.
Laboratory Values at Baseline and on Final Subcutaneous Testosterone Dose, at and Across Three Dose Ranges
| Parameter, mean (SD), [p value] for each Δ at each SC-T dose | SC-T/month, <160 mg (n=28) | SC-T/month, 160–240 mg (n=81) | SC-T/month, >240 mg (n=10) | Overall (n=119) | Trend across dose range: p-value |
|---|---|---|---|---|---|
| Baseline total T, ng/dL | 29.2 (14.8) | 31.6 (13.6) | 37.8 (15.8) | 31.6 (14.1) | 0.269 |
| Final total T, ng/dL | 328.8 (185.5) | 456.8 (190.6) | 522.6 (162.6) | 432.2 (195.4) | 0.003 |
| Δ total T, ng/dL | 287.1 [a] | 424.6 [a] | 484.7 [a] | 399.3 [a] | 0.003 |
| Baseline free T, pg/mL | 3.8 (3.7) | 3.6 (2.4) | 4.5 (1.8) | 3.7 (2.6) | 0.619 |
| Final free T, pg/mL | 53.9 (30.9) | 91.9 (45.3) | 124.6 (47.9) | 86.2 (46.5) | a |
| Δ free T, pg/mL | 47.2 [a] | 89.3 [a] | 120.1 [a] | 84.3 [a] | a |
| Baseline estradiol, pg/mL | 81.3 (70.4) | 79.6 (71.1) | 68.6 (52.66) | 78.9 (69.0) | 0.894 |
| Final estradiol, pg/mL | 52.9 (31.2) | 48.4 (50.3) | 47.3 (28.6) | 49.1 (45.7) | 0.938 |
| Δ Estradiol, pg/mL | −67.6 [0.036] | −30.7 [0.001] | −27.0 [0.293] | 34.7 [a] | 0.372 |
| Baseline TC, mg/dL | 161.0 (28.8) | 156.2 (29.8) | 165.2 (33.9) | 158.0 (29.8) | 0.575 |
| Final TC, mg/dL | 155.6 (28.0) | 151.8 (32.3) | 170.7 (25.5) | 154.6 (31.1) | 0.202 |
| Δ TC, mg/dL | −5.4 [0.362] | −4.5 [0.182] | 5.5 [0.452] | −3.5 [0.194] | 0.497 |
| Baseline HDL-C, mg/dL | 50.4 (15.0) | 50.2 (13.2) | 47.6 (8.5) | 50.0 (13.2) | 0.833 |
| Final HDL-C, mg/dL | 45.6 (12.6) | 43.5 (9.3) | 39.5 (7.5) | 43.4 (9.8) | 0.301 |
| Δ HDL-C, mg/dL | −3.7 [0.08] | 6.7 [a] | −8.1 [0.016] | 6.4 [a] | 0.488 |
| Baseline LDL-C, mg/dL | 90.4 (22.6) | 90.4 (25.4) | 101.3 (28.8) | 91.4 (25.1) | 0.427 |
| Final LDL-C, mg/dL | 93.0 (26.2) | 91.1 (24.5) | 104.3 (22.2) | 92.9 (24.7) | 0.296 |
| Δ LDL-C, mg/dL | 0.4 [0.928] | −0.4 [0.899] | 2.9 [0.602] | 0.2 [0.922] | 0.883 |
| Baseline TG, mg/dL | 96.9 (38.8) | 87.6 (34.0) | 87.5 (38.5) | 89.6 (35.4) | 0.541 |
| Final TG, mg/dL | 96.8 (42.5) | 97.5 (59.3) | 128.6 (86.4) | 100.8 (60.5) | 0.309 |
| Δ TG, mg/dL | −1.3 [0.926] | 9.0 [0.276] | 41.1 [0.092] | 11.4 [0.100] | 0.237 |
| Baseline hematocrit, % | 39.4 (2.7) | 39.1 (2.5) | 40.1 (2.7) | 39.2 (2.6) | 0.48 |
| Final hematocrit, % | 43.1 (3.1) | 44.1 (3.3) | 46.5 (3.3) | 44.1 (3.3) | 0.024 |
| Δ Hematocrit, % | 3.7 [a] | 5.1 [a] | 6.4 [a] | 4.9 [a] | 0.054 |
| Baseline AST, U/L | 24.4 (10.3) | 21.3 (7.3) | 19.0 (4.6) | 21.8 (8.0) | 0.115 |
| Final AST, U/L | 20.8 (7.3) | 23.6 (9.5) | 23.4 (7.0) | 23.0 (8.8) | 0.349 |
| Δ AST, U/L | −4.3 [0.024] | 2.4 [0.060] | 4.4 [0.078] | 1.1 [0.290] | 0.010 |
| Baseline ALT, U/L | 20.1 (11.2) | 21.0 (9.7) | 20.3 (10.5) | 20.8 (10.0) | 0.908 |
| Final ALT, U/L | 18.4 (9.6) | 21.3 (13.8) | 30.0 (9.7) | 21.4 (12.9) | 0.050 |
| Δ ALT, U/L | −2.0 [0.353] | 0.4 [0.824] | 9.7 [0.041] | 0.7 [0.600] | 0.054 |
Δ is the change from baseline to final testosterone dose. Values in parentheses for each laboratory value is SD, and in brackets for the Δ it is the p-value indicating if that change is significant.
Statistical significance: ap<0.001.
HDL-C, high-density lipoprotein cholesterol; LDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.